Bicycle Therapeutics PLC
NASDAQ:BCYC
Intrinsic Value
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserv... [ Read More ]
The intrinsic value of one BCYC stock under the Base Case scenario is 11.23 USD. Compared to the current market price of 22.67 USD, Bicycle Therapeutics PLC is Overvalued by 50%.
Valuation Backtest
Bicycle Therapeutics PLC
Run backtest to discover the historical profit from buying and selling BCYC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bicycle Therapeutics PLC
Current Assets | 561.9m |
Cash & Short-Term Investments | 526.4m |
Receivables | 24m |
Other Current Assets | 11.4m |
Non-Current Assets | 33.5m |
PP&E | 27.7m |
Other Non-Current Assets | 5.8m |
Current Liabilities | 69.5m |
Accounts Payable | 13.1m |
Accrued Liabilities | 31.3m |
Other Current Liabilities | 25.2m |
Non-Current Liabilities | 154.9m |
Long-Term Debt | 30.7m |
Other Non-Current Liabilities | 124.2m |
Earnings Waterfall
Bicycle Therapeutics PLC
Revenue
|
27m
USD
|
Operating Expenses
|
-216.3m
USD
|
Operating Income
|
-189.4m
USD
|
Other Expenses
|
8.7m
USD
|
Net Income
|
-180.7m
USD
|
Free Cash Flow Analysis
Bicycle Therapeutics PLC
BCYC Profitability Score
Profitability Due Diligence
Bicycle Therapeutics PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Bicycle Therapeutics PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
BCYC Solvency Score
Solvency Due Diligence
Bicycle Therapeutics PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Bicycle Therapeutics PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BCYC Price Targets Summary
Bicycle Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for BCYC is 44.06 USD with a low forecast of 30.3 USD and a high forecast of 63 USD.
Ownership
BCYC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BCYC Price
Bicycle Therapeutics PLC
Average Annual Return | 59.42% |
Standard Deviation of Annual Returns | 118.11% |
Max Drawdown | -79% |
Market Capitalization | 858.7m USD |
Shares Outstanding | 37 880 300 |
Percentage of Shares Shorted | 6.79% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 119 full-time employees. The company went IPO on 2019-05-23. The firm is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, a tumor antigen in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets membrane type 1 matrix metalloproteinase (MT1-MMP) is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the center for drug development of cancer research United Kingdom. The Company’s immune-oncology products include BT7480, BT7455 and BT7401. BT7480 is a TICA that targets CD137 and Nectin-4. BT7455 is a TICA targeting EphA2 and CD137. BT7401 is an agonistic Bicycle built from multiple CD137 monomeric Bicycles.
Contact
IPO
Employees
Officers
The intrinsic value of one BCYC stock under the Base Case scenario is 11.23 USD.
Compared to the current market price of 22.67 USD, Bicycle Therapeutics PLC is Overvalued by 50%.